TY - JOUR
T1 - Combination treatment of interferon β-1b and warfarin for a patient with baló's concentric sclerosis and antiphospholipid syndrome
AU - Tso, An Chen
AU - Tsao, Wen Long
AU - Chen, Cheng Yu
AU - Yang, Chwan Fen
AU - Peng, Giia Sheun
PY - 2015/1/2
Y1 - 2015/1/2
N2 - Background: Baló's concentric sclerosis (BCS), a rare variant of multiple sclerosis (MS), as the initial presentation of antiphospholipid syndrome (APS) is unusual. The pathogenic role of antiphospholipid antibodies in the development of MS remains unknown. Anticoagulant therapy might be used in patients with MS and APS for prevention against the relapse of MS. Case Report: We present a 27-year-old man diagnosed as BCS with APS. Initially, after corticosteroid therapy, he exhibited a complete recovery. During follow-up, his Baló-like lesion dissolved over time but transformed into other asymptomatic MS-like lesions. He also had persistently elevated anticardiolipin IgG levels. The patient was, therefore, on a combined therapy of interferon β-1b and an anticoagulant agent. No new brain lesions were found on 2 occasional head magnetic resonance imaging studies at 1 year follow-up. Conclusions: To prevent further MS relapse and thrombotic complications of APS, a combined therapy of interferon β-1b and an anticoagulant agent can be an important strategy in treating patients with both BCS and APS.
AB - Background: Baló's concentric sclerosis (BCS), a rare variant of multiple sclerosis (MS), as the initial presentation of antiphospholipid syndrome (APS) is unusual. The pathogenic role of antiphospholipid antibodies in the development of MS remains unknown. Anticoagulant therapy might be used in patients with MS and APS for prevention against the relapse of MS. Case Report: We present a 27-year-old man diagnosed as BCS with APS. Initially, after corticosteroid therapy, he exhibited a complete recovery. During follow-up, his Baló-like lesion dissolved over time but transformed into other asymptomatic MS-like lesions. He also had persistently elevated anticardiolipin IgG levels. The patient was, therefore, on a combined therapy of interferon β-1b and an anticoagulant agent. No new brain lesions were found on 2 occasional head magnetic resonance imaging studies at 1 year follow-up. Conclusions: To prevent further MS relapse and thrombotic complications of APS, a combined therapy of interferon β-1b and an anticoagulant agent can be an important strategy in treating patients with both BCS and APS.
KW - anticoagulant
KW - antiphospholipid syndrome
KW - Baló's concentric sclerosis
KW - multiple sclerosis
KW - susceptibility-weighted imaging
UR - http://www.scopus.com/inward/record.url?scp=84922032262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922032262&partnerID=8YFLogxK
U2 - 10.1097/NRL.0000000000000002
DO - 10.1097/NRL.0000000000000002
M3 - Article
C2 - 25607332
AN - SCOPUS:84922032262
VL - 19
SP - 46
EP - 48
JO - Neurologist
JF - Neurologist
SN - 1074-7931
IS - 2
ER -